A D Michelson1, M R Barnard, L A Krueger, C R Valeri, M I Furman. 1. Center for Platelet Function Studies, Departments of Pediatrics and Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA. michelson@platelets.org
Abstract
BACKGROUND: Platelet surface P-selectin is considered the "gold standard" marker of platelet activation. Degranulated, P-selectin-positive platelets, however, aggregate with leukocytes in vitro and rapidly lose surface P-selectin in vivo. METHODS AND RESULTS: Flow cytometric tracking of autologous, biotinylated platelets in baboons enabled us to directly demonstrate for the first time in vivo that (1) infused degranulated platelets very rapidly form circulating aggregates with monocytes and neutrophils, and (2) 30 minutes after infusion of the degranulated platelets, the percentage of circulating monocytes aggregated with infused platelets persist at high levels, whereas the percentage of circulating neutrophils aggregated with infused platelets and the platelet surface P-selectin of nonaggregated infused platelets return to baseline. We therefore performed 2 clinical studies in patients with acute coronary syndromes. First, after percutaneous coronary intervention (n=10), there was an increased number of circulating monocyte-platelet (and to a lesser extent, neutrophil-platelet) aggregates but not P-selectin-positive platelets. Second, of 93 patients presenting to an Emergency Department with chest pain, patients with acute myocardial infarction (AMI) (n=9) had more circulating monocyte-platelet aggregates (34.2+/-10.3% [mean+/-SEM]) than patients with no AMI (n=84, 19.3+/-1.4%, P<0.05) and normal control subjects (n=10, 11.5+/-0.8%, P<0.001). Circulating P-selectin-positive platelets, however, were not increased in chest pain patients with or without AMI. CONCLUSIONS: As demonstrated by 3 independent means (in vivo tracking of activated platelets in baboons, human coronary intervention, and human AMI), circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin.
BACKGROUND: Platelet surface P-selectin is considered the "gold standard" marker of platelet activation. Degranulated, P-selectin-positive platelets, however, aggregate with leukocytes in vitro and rapidly lose surface P-selectin in vivo. METHODS AND RESULTS: Flow cytometric tracking of autologous, biotinylated platelets in baboons enabled us to directly demonstrate for the first time in vivo that (1) infused degranulated platelets very rapidly form circulating aggregates with monocytes and neutrophils, and (2) 30 minutes after infusion of the degranulated platelets, the percentage of circulating monocytes aggregated with infused platelets persist at high levels, whereas the percentage of circulating neutrophils aggregated with infused platelets and the platelet surface P-selectin of nonaggregated infused platelets return to baseline. We therefore performed 2 clinical studies in patients with acute coronary syndromes. First, after percutaneous coronary intervention (n=10), there was an increased number of circulating monocyte-platelet (and to a lesser extent, neutrophil-platelet) aggregates but not P-selectin-positive platelets. Second, of 93 patients presenting to an Emergency Department with chest pain, patients with acute myocardial infarction (AMI) (n=9) had more circulating monocyte-platelet aggregates (34.2+/-10.3% [mean+/-SEM]) than patients with no AMI (n=84, 19.3+/-1.4%, P<0.05) and normal control subjects (n=10, 11.5+/-0.8%, P<0.001). Circulating P-selectin-positive platelets, however, were not increased in chest painpatients with or without AMI. CONCLUSIONS: As demonstrated by 3 independent means (in vivo tracking of activated platelets in baboons, human coronary intervention, and human AMI), circulating monocyte-platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-selectin.
Authors: Matthew T Rondina; BreAnna Brewster; Colin K Grissom; Guy A Zimmerman; Diana H Kastendieck; Estelle S Harris; Andrew S Weyrich Journal: Chest Date: 2012-03-01 Impact factor: 9.410
Authors: D J H McCabe; P Harrison; I J Mackie; P S Sidhu; G Purdy; A S Lawrie; H Watt; S J Machin; M M Brown Journal: J Neurol Neurosurg Psychiatry Date: 2005-09 Impact factor: 10.154
Authors: Matthew T Rondina; Jason M Lappé; John F Carlquist; Joseph B Muhlestein; Matthew J Kolek; Benjamin D Horne; Robert R Pearson; Jeffrey L Anderson Journal: Cardiology Date: 2007-08-27 Impact factor: 1.869
Authors: Michal Heger; Rowan F van Golen; Mans Broekgaarden; Renate R van den Bos; H A Martino Neumann; Thomas M van Gulik; Martin J C van Gemert Journal: Lasers Med Sci Date: 2014-03 Impact factor: 3.161
Authors: Adriana Vieira-de-Abreu; Robert A Campbell; Andrew S Weyrich; Guy A Zimmerman Journal: Semin Immunopathol Date: 2011-08-06 Impact factor: 9.623
Authors: Monica Periasamy; David C Lieb; Matthew J Butcher; Norine Kuhn; Elena Galkina; Mark Fontana; Stephen Wohlgemuth; Jerry L Nadler; Yuliya Dobrydneva Journal: Obes Surg Date: 2014-08 Impact factor: 4.129